Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBiohaven Ltd.

Biohaven Ltd.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
14.48 USD 0.58 ( 4.17%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1875450
Market Cap
1532.79M

Momentum Score

…

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.76
Low
14.49
High
52 Week Price Range
7.48
Low
24.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biohaven Ltd is a commercial-stage biopharmaceutical focused on neurological disorders, known for rimegepant, an oral CGRP antagonist approved for acute and preventive migraine. Long-term growth may come from further adoption and label expansion of its migraine franchise, international launches and progress of pipeline candidates. Investors may find appeal in an established commercial product and a focused neurology platform.

Key risks include reliance on a limited product portfolio, intense CGRP-market competition, pricing and reimbursement pressure, and clinical or regulatory setbacks for pipeline programs.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
13.90
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
5.36
ROE
-310.75%
Net Debt
48.90M
ROCE
-219.78%
Diluted EPS TTM
-6.86

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -737.38M -845.69M -409.55M -569.84M -212.43M
Minority interest - - - - -1.81M
Net income -738.82M -846.42M -408.17M -570.28M -213.80M
Selling general administrative 106.17M 89.24M 56.90M 130.86M 37.41M
Selling and marketing expenses - - 5.87M - -
Gross profit -4.14M -3.92M -3.37M -1.39M 370.85M
Reconciled depreciation 9.92M 7.86M 6.91M 1.39M 1.39M
Ebit -737.38M -885.11M -436.05M -464.19M -218.90M
Ebitda -727.46M -877.26M -429.14M -462.80M -217.51M
Depreciation and amortization 9.92M 7.86M 6.91M 1.39M 1.39M
Non operating income net other - - - - -65.44M
Operating income -745.38M -885.11M -436.05M -567.93M -218.90M
Other operating expenses 745.38M 885.11M 436.05M 567.93M 218.90M
Interest expense - - - 1.39M 41.55M
Tax provision 1.44M 0.73M -1.38M 0.44M 1.37M
Income tax expense 1.44M 0.73M -1.38M 0.44M 1.37M
Total revenue 0.00M 0.00M 0.00M 0.00M 462.51M
Total operating expenses 741.24M 885.11M 436.05M 567.93M 218.90M
Cost of revenue 4.14M 3.92M 3.37M 1.39M 91.66M
Total other income expense net 8.00M 39.42M 26.50M -1.91M 6.47M
Net income from continuing ops -738.82M -846.42M -408.17M -570.28M -848.40M
Net income applicable to common shares - - - -570.28M -846.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 451.45M 615.11M 513.21M 661.78M 142.06M
Intangible assets 18.40M 18.40M 18.40M 18.40M 18.40M
Other current assets 49.19M 49.88M 47.38M 19.33M 2.12M
Total liab 399.38M 191.67M 85.24M 123.01M 47.37M
Total stockholder equity 52.07M 423.44M 427.98M 538.77M 34.69M
Deferred long term liab - - - - 13.11M
Other current liab 104.29M 132.40M 36.54M 79.32M 37.16M
Common stock 1934.28M 1656.70M 887.53M 615.74M 1676.79M
Capital stock 1934.28M 1656.70M 887.53M 615.74M -
Retained earnings -2084.54M -1345.71M -499.29M -91.12M -2585.76M
Other liab - - - 2.41M 2.64M
Good will 1.39M 1.39M 1.39M 1.39M 1.39M
Other assets - - 0.00M 2.58M 3.22M
Cash 229.96M 99.13M 248.40M 204.88M 76.06M
Total current liabilities 115.93M 154.23M 55.42M 90.02M 41.94M
Net debt 48.90M -62.55M -217.53M -174.30M 550.66M
Short term debt - 3.80M 3.31M - 62.50M
Short long term debt total 278.86M 36.58M 30.88M 30.58M 626.72M
Other stockholder equity 193.98M 112.37M 39.80M 13.87M 169.66M
Property plant equipment - - - 52.14M 14.69M
Total current assets 368.33M 538.47M 442.45M 586.97M 94.82M
Long term investments - - - 0.00M 6.00M
Net tangible assets - - - 518.68M -735.82M
Short term investments 89.18M 386.86M 133.42M 260.46M 192.65M
Net receivables - 2.60M 13.65M 46.14M 9.91M
Long term debt 238.90M - - - 626.72M
Inventory - - -0.40M 56.16M 6.73M
Accounts payable 11.64M 18.03M 15.58M 10.70M 4.78M
Noncontrolling interest in consolidated entity - - - - -3.63M
Accumulated other comprehensive income 8.35M 0.08M -0.07M 0.28M -0.07M
Common stock total equity - - - - 1676.79M
Retained earnings total equity - - - - -2585.76M
Non currrent assets other 47.36M 3.13M 2.40M 2.58M 3.22M
Non current assets total 83.12M 76.64M 70.77M 74.81M 47.24M
Capital lease obligations 45.71M 36.58M 30.88M 30.58M -
Long term debt total - - - - 626.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 303.12M -244.97M 129.83M -304.79M 28.27M
Change to liabilities - - - 5.93M 117.20M
Total cashflows from investing activities 300.56M -244.97M 129.83M -304.79M 26.55M
Net borrowings 250.00M 0.00M 0.00M - 420.44M
Total cash from financing activities 439.12M 677.77M 211.91M 767.60M 138.45M
Change to operating activities - - - -34.53M 0.64M
Net income -738.82M -846.42M -408.17M -570.28M -213.80M
Change in cash 130.24M -149.58M 9.52M 165.55M -6.45M
Begin period cash flow 102.54M 252.12M 242.60M 77.06M 83.51M
End period cash flow 232.78M 102.54M 252.12M 242.60M 77.06M
Total cash from operating activities -609.44M -582.45M -331.73M -297.69M -145.84M
Issuance of capital stock 189.18M 666.16M 243.22M 283.80M -
Depreciation 9.92M 7.86M 6.91M 1.39M 1.39M
Other cashflows from investing activities -1.85M 0.39M - - -
Change to inventory - - - - -24.10M
Change to account receivables - - - - -188.16M
Sale purchase of stock 1.83M 11.50M - - 345.63M
Other cashflows from financing activities -0.19M 2.26M -31.32M 483.79M 138.45M
Change to netincome - - - 299.81M 128.66M
Capital expenditures 0.71M 4.05M 3.05M 41.07M 0.94M
Change receivables - - - - -188.16M
Cash flows other operating - - - - -41.24M
Cash and cash equivalents changes - - - - 40.30M
Change in working capital 1.36M 16.81M 24.61M -28.60M 1.66M
Stock based compensation 112.36M 71.96M 28.79M 193.56M 65.64M
Other non cash items 5.74M 167.34M 16.13M 106.25M 4.52M
Free cash flow -610.15M -586.50M -334.77M -338.76M -146.78M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BHVN
Biohaven Ltd.		 0.58
4.17%		 14.48 - - - 31.26 -2.19
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Biohaven Ltd.

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

215 Church Street, New Haven, CT, United States, 06510

203 404 0410

https://www.biohaven.com

274

Name Title Year Born
Dr. Vladimir Coric M.D. Chairman & CEO 1971
Mr. Matthew Buten Chief Financial Officer 1961
Mr. George C. Clark VP & Chief Accounting Officer 1984
Dr. Bruce D. Car DACVP, Ph.D. Chief Scientific Officer 1961
Ms. Jennifer Porcelli VP of Investor Relations NA
Mr. Warren Volles Gen. Counsel & Chief Legal Officer NA
Mr. Clifford Bechtold M.S. Chief Compliance Officer NA
Ms. Kimberly Gentile Sr. VP of Clinical Operations 1966
Mr. John Tilton Chief Commercial Officer of Rare Diseases 1968
Mr. Chris Barrett Sr. VP of Commercial Strategy, Common Disease NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…